Helixgate

Helixgate

Uncategorized

Text Mining Culture Conditions and Glycosylation Relationships

Published

on

A novel data gathering approach that relies on “text mining” can help process developers better understand the complex relationships between culture conditions and glycosylation, say the authors of new research.

A protein’s glycosylation profile—the pattern of glycan residues that bind to the core molecule during production—dictates its therapeutic function and efficacy. A reproducible profile is key to achieving quality and consistency goals.

And, for the most part, biopharma is good at using experimentation to understand how changes to culture conditions are likely to impact glycosylation processes for a given developmental manufacturing process.

Industry has been less adept at using these experimental findings to develop generalized glycosylation relationship models, says Chuming Chen, PhD, a professor at the Delaware Biotechnology Institute at the University of Delaware.

“Despite the extensive body of published work, general relationships between different cell culture conditions and glycosylation profiles remain fragmented across diverse studies. Fragmentation in our knowledge of causes of specific glycan profiles is partially a result of variables and conditions changing from one context to another, and these are not always easily tracked,” he tells GEN.

Test mining and knowledge graphs

With this in mind, Chen, colleagues, and scientists at Waters who co-authored the study, developed an automated way of gathering data from multiple sources—using a technique called “text mining”—and elucidating relationships between various conditions and glycosylation.

“First, we designed a specialized text mining pipeline to automatically extract relationships between cell culture conditions and glycosylation profiles with an 88% accuracy from unstructured scientific literature, eliminating the need for manual curation,” Chen explains.

The researchers then used a normalization strategy to reconcile inconsistencies in the extracted information to ensure consistency.

“These standardized entities and the relationships among them were used to build a unified Knowledge Graph [called the Bioprocess Knowledge Graph Database], which captures both direct and hidden, indirect associations between process parameters and therapeutic glycan outcomes.

“Finally, we developed a web interface that enables researchers to dynamically query, explore, and visualize these complex relationships, ultimately facilitating more informed decision-making in therapeutic protein manufacturing,” he says.

The approach has application in biopharmaceutical manufacturing, according to Chen, who suggests it can be used to guide early-phase process development.

“The benefit to biopharmaceutical manufacturing process researchers is to identify specific contexts and conditions that may increase or decrease the target glycan structure. Because glycan structure can sometimes impact the mechanism of action or drug-patient interactions, this can be highly useful information,” he adds.

Looking forward, Chen and his co-authors plan to expand their system to include more information that is relevant to production.

“Our final product is an interface that is queryable and visualizable. Although it has been developed as a prototype, this is automated and can be extended to incorporate more information related to biopharmaceutical manufacturing. We are currently extending our project to include deep learning and LLM for relation extraction,” he says.

The post Text Mining Culture Conditions and Glycosylation Relationships appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Uncategorized

Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins

Published

on

You know when you are at the eye doctor getting an updated prescription, and suddenly the world snaps into sharper focus? Physicists at the University of California (UC), Berkeley, have now done something similar for electron microscopy. By introducing phase contrast into a cryo‑electron microscope, they have delivered dramatically sharper images of some of biology’s smallest and most elusive proteins.

The advance comes from a new laser phase plate (LPP), described in the paper “Laser phase plate improves structure determination of small proteins by cryo‑EM,” which was published recently in Science. Led by physicist Holger Mueller, PhD, of UC Berkeley and Lawrence Berkeley National Laboratory, the team demonstrated that a laser‑driven phase plate can overcome one of cryo‑EM’s most persistent limitations: poor contrast for small proteins.

Cryo-EM images of two proteins, apoferritin and hemoglobin, taken without and with a laser phase plate. The images are analyzed in a computer to produce detailed 3D structures of the proteins. [Holger Müller, Jessie Zhang/UC Berkeley]

Cryo‑EM has transformed structural biology over the past decade, earning a Nobel Prize in 2017 for enabling high‑resolution structures without crystallization. But despite its impact, the technique still struggles with proteins below ~70 kilodaltons—a size range that includes about 90% of the human proteome. “Because of signal-to-noise limitations, the majority of human and animal proteins are too small to be analyzed by these methods [cryo-EM and cryoelectron tomography]. The increase in signal-to-noise ratio provided by this laser phase plate is expected to overcome these important limitations.”

The new LPP begins to address that problem. The LPP uses an intense, continuous‑wave laser to shift the phase of the electron beam itself. This produces true phase contrast without dimming or destabilizing the beam. Mueller described the laser focus as “75 kilowatts focused to a few microns… That’s more powerful than what you use for welding. It has more power than a military laser. It builds up the brightest continuous laser focus ever.”

Installed in a custom Thermo Fisher Titan Krios, the LPP immediately improved the clarity and resolvability of small proteins, including hemoglobin, which sits at the lower limit of what today’s cryo‑EM instruments can handle. As the authors wrote in the abstract: “Here, we show that the laser phase plate (LPP)… enhances the resolution in single-particle reconstruction of small proteins by improving specimen-motion correction, recovery of information from the early frames, as well as particle visualization, 3D classification, and alignment.”

phase plate cover Cryo-EM
A laser (purple) is powerfully amplified by highly polished mirrors and focused on the electron beam (blue) to shift its phase and increase the cryo-EM microscope’s contrast, allowing biologists to image smaller proteins and the crowded structures inside cells. [Sayo Studio]

These improvements were achieved using standard defocus ranges and reconstruction workflows. “For the most challenging cases—small particles, bad specimens—the laser produces a very considerable advantage,” Mueller said.

 

The impact extends beyond single‑particle analysis. Cryo‑electron tomography (cryo‑ET), which assembles multiple angular views of a molecule or protein into a three-dimensional image, stands to benefit even more. “With cryo-ET, we’re looking at small, very complicated cellular material that’s incredibly crowded inside the cell,” said Bridget Carragher, PhD, founding technical director of imaging at Biohub. “It’s like a forest of trees, and you’re trying to find one leaf on one tree in there. Cryo-ET needs a dramatic step forward in contrast, so we can start to see what’s going on inside the cell. That’s what the laser phase plate promises to give us.”

Biohub is developing a dual‑laser version of the system, designed to reduce component wear and minimize aberrations. Meanwhile, Mueller’s team is pushing toward imaging proteins as small as 17 kilodaltons, a threshold that would open access to vast regions of the human proteome previously invisible to cryo‑EM.

“This technology is a step function change for biology,” said Stephani Otte, PhD, Biohub’s vice president of imaging science. “What was once invisible will become visible—and that changes everything about how we understand disease.”

“The bottom line is, if you have a large protein and a really good sample—a fresh one or one frozen without bubbles, for example—you may not need the phase plate to get a single, high-quality image. But for a small protein and a bad sample, laser-on is best,” Mueller said. “This could fill an enormous gap in our knowledge of protein structures that can’t be crystallized or are too small for today’s cryo-EM. And it will be revolutionary for cryo-ET.”

The post Laser‑Driven Phase Contrast Enhances Cryo‑EM Resolution of Small Proteins appeared first on GEN – Genetic Engineering and Biotechnology News.

Continue Reading

Uncategorized

STAT+: Updated: Tracking RFK Jr.’s promises to remake health in America

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Published

on

Updated June 11, 2026

WASHINGTON — A pledge to “Make America Healthy Again” earned Robert F. Kennedy Jr. his job atop U.S. health agencies a year and some change ago. He’s now had the opportunity to turn his words into action, with mixed results.  

“All one needs” to prove the health secretary’s attentiveness is to “review my unprecedented list of accomplishments on a wide range of issues, all of which I drove,” Kennedy posted on X on Wednesday in response to a journalist.

Continue to STAT+ to read the full story…

Read More

Continue Reading

Uncategorized

An obesity drug deep-dive, and peptides move mainstream

Published

on

Can any of the new obesity medications in development stand out from the pack? Which company just broke records with its IPO? And will the Food and Drug Administration allow greater access to experimental peptides?

We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.

Read the rest…

Continue Reading
Advertisement

Trending